Acute Myeloid Leukemia Clinical Trial
— VenExOfficial title:
Two-stage, Two-arm, Open-Label Phase II Study of Venetoclax in Combination With Azacytidine in Acute Myeloid Leukemia Patients Selected Using Ex Vivo Drug Sensitivity Screening
Verified date | December 2022 |
Source | Helsinki University Central Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi center two-stage, two-arm, open label phase II study of venetoclax in combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex vivo venetoclax sensitivity screening. This study will characterize the usability of ex vivo drug sensitivity testing for patient selection for selecting the responsive patients for venetoclax therapy. The exploratory study will aim to find novel combinations for overcoming resistance as well as finding/validating biomarkers for both sensitivity and resistance.
Status | Active, not recruiting |
Enrollment | 104 |
Est. completion date | February 1, 2024 |
Est. primary completion date | February 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent 2. Patients who present with one of the following (except acute promyelocytic leukemia): - De novo or secondary AML patients who are non-fit for standard induction therapy (see below) - Relapsed or refractory AML patients following at least 1 line of prior therapies (see below) 3. Ex vivo sensitivity testing performed to assess venetoclax sensitivity 1. Validation cohort: All participants are treated with venetoclax+azacitidine irrespective of the ex vivo screening results. 2. Study cohort: Only the participants exhibiting ex vivo sensitivity to venetoclax are included to study therapy. 4. Participant must have ECOG Performance status = 2 for participants = 75 years of age OR = 3 for participants = 18 to 74 years of age 5. Leukocyte count < 25 x10E9/l. Hydroxyurea use is permitted to meet this criterion. 6. Participant must have adequate renal function as demonstrated by a calculated creatinine clearance = 30 mL/min; determined by the Cockcroft Gault formula. 7. Participant must have adequate liver function as demonstrated by 1. alanine aminotransferase (ALT) = 4.0 × ULN 2. bilirubin = 1.5 × ULN 8. Specific inclusion criteria for participants non-fit for standard chemotherapy Participant must be: = 70 years of age OR = 18 to 69 years of age and ineligible for intensive chemotherapy meeting at least one of the criteria following: - Clinically significant comorbidities, reflected at least 1 of: - Left ventricular ejection fraction (LVEF) < 50%. - Lung diffusion capacity for carbon monoxide (DLCO) = 65% of expected. - Forced expiratory volume in 1 second (FEV1) = 65% of expected. - Chronic stable angina or congestive heart failure controlled with medication. - Alanine aminotransferase (ALT) 3.0-4.0 × ULN - Other contraindication(s) to anthracycline therapy (must be documented) - Adverse risk karyotype associated with poor outcome with standard chemotherapy - Patient's refusal from intensive chemotherapy 9. Specific inclusion criteria for relapsed patients Participant must be = 55 years of age with non-CBF AML relapse OR = 18 of age and meeting at least one of the criteria following: - Not candidate for intensive chemotherapy (see the criteria 8.) - The duration of remission < 12 months. - Relapse after allogeneic transplantation. - 2nd (or higher) relapse. 10. Specific inclusion criteria for refractory patients The patients who fail to achieve a complete or partial remission after induction chemotherapy (two cycles of chemotherapy containing cytarabine or clofarabine, in compilation with topoisomerase II inhibitor (e.g. anthracycline or mitoxantrone) Exclusion Criteria: 1. Participant has acute promyelocytic leukemia (APL) 2. The leukemic cell content (blast percentage) in bone marrow/peripheral blood (depending which is used for drug sensitivity testing) is = 10 % 3. ECOG >3 (see also inclusion criteria 4) 4. Participant has known CNS involvement with AML (note: CSF or radiological investigations are not required without clinical suspicion) 5. Participant with known HIV infection or active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection that is not controlled with anti-viral medication. 6. Participant has cardiovascular disability status of New York Heart Association Class = 2. Class 2 is defined as cardiac disease in which participants are comfortable at rest but ordinary physical activity results in palpitations, fatigue, dyspnea, or anginal pain. 7. Evidence of clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participation in this study (including but not limited to): 1. Participant has a chronic respiratory disease that requires continuous oxygen use 2. Systemic uncontrolled infection requiring therapy (viral, bacterial or fungal) 3. Malabsorption syndrome or other condition that precludes enteral route of administration. 4. Uncontrolled GVHD. 8. Participant has a history of other malignancies prior to study entry, with the exception of previous malignancy treated with curative intent. |
Country | Name | City | State |
---|---|---|---|
Finland | HelsinkiUCH | Helsinki | Uusimaa |
Lead Sponsor | Collaborator |
---|---|
Helsinki University Central Hospital |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete remission (CR)/complete remission rate with incomplete hematologic recovery (CRi) rate in study cohort after three cycles. | The bone marrow is examined at the end of Cycle 3. Each cycle is 28 days. | ||
Secondary | The correlation of ex vivo venetoclax sensitivity and specific responses: Overall Survival (OS), Duration of Response (DOR), Event-free Survival (EFS) and Minimal Residual Disease (MRD) status. | Through study completion, an average of 3 years | ||
Secondary | The correlation of venetoclax blood concentrations to specific responses: Overall Survival (OS), Duration of Response (DOR), Event-free Survival (EFS) and Minimal Residual Disease (MRD) status. | Through study completion, an average of 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |